Abstract
Screening Pfizer's compound library resulted in the identification of weak acetyl-CoA carboxylase inhibitors, from which were obtained rACC1 CT-domain co-crystal structures. Utilizing HTS hits and structure-based drug discovery, a more rigid inhibitor was designed and led to the discovery of sub-micromolar, spirochromanone non-specific ACC inhibitors. Low nanomolar, non-specific ACC-isozyme inhibitors that exhibited good rat pharmacokinetics were obtained from this chemotype.
2010 Elsevier Ltd. All rights reserved.
MeSH terms
-
Acetyl-CoA Carboxylase / antagonists & inhibitors*
-
Acetyl-CoA Carboxylase / metabolism*
-
Animals
-
Enzyme Inhibitors / chemistry*
-
Enzyme Inhibitors / pharmacokinetics
-
Enzyme Inhibitors / pharmacology*
-
Humans
-
Isoenzymes / antagonists & inhibitors
-
Isoenzymes / metabolism
-
Models, Molecular
-
Rats
-
Small Molecule Libraries / chemistry*
-
Small Molecule Libraries / pharmacokinetics
-
Small Molecule Libraries / pharmacology*
-
Structure-Activity Relationship
Substances
-
Enzyme Inhibitors
-
Isoenzymes
-
Small Molecule Libraries
-
Acetyl-CoA Carboxylase